Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans-Reference-Cited by-同舟云学术

Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans

Published:2015-05-15 Issue:2 Volume:37 Page:93-106
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Wang Haiqing¹,Rangan Vangipuram S.²,Sung Mei-Chen²,Passmore David²,Kempe Thomas²,Wang Xiaoli³,Thevanayagam Lourdes²,Pan Chin²,Rao Chetana²,Srinivasan Mohan²,Zhang Qian²,Gangwar Sanjeev²,Deshpande Shrikant²,Cardarelli Pina²,Marathe Punit¹,Yang Zheng¹

Affiliation:

1. Metabolism and Pharmacokinetics; Bristol-Myers Squibb; Princeton NJ United States

2. Biologics Discovery California; Bristol-Myers Squibb; Redwood City CA United States

3. Clinical Pharmacology; Bristol-Myers Squibb; Princeton NJ United States

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.1953/fullpdf

Reference37 articles.

1. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor;Goodwin;Cell,1993

2. The cloning of CD70 and its identification as the ligand for CD27;Bowman;J Immunol,1994

3. CD70 represents the human ligand for CD27;Hintzen;Int Immunol,1994

4. Characterization of the human CD27 ligand, a novel member of the TNF gene family;Hintzen;J Immunol,1994

5. CD70 represents the human ligand for CD27;Hintzen;Int Immunol,1994

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma;Clinical Genitourinary Cancer;2023-12

2. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs);Xenobiotica;2022-08-03

3. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress;Drug Discovery Today;2021-08

4. Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer;Cells;2021-04-12

5. How can the potential of the duocarmycins be unlocked for cancer therapy?;Drug Discovery Today;2021-02